21 results about "Metered-dose inhaler" patented technology

Systems and methods for isolating and / or desiccating a portion of a drug delivery tract of a drug delivery apparatus to reduce water vapor content therein are provided. For example, there is provided a metered dose inhaler for delivering aerosolized medicament or other matter to a user. The aerosolized medicament or other matter may be discharged from a discharge passageway within the inhaler into an inhalation passageway for inhalation by a user, and the inhaler may comprise a seal member operative to selectively isolate the discharge passageway from the inhalation passageway and external environment during inactivity. The inhaler may further comprise a desiccant material arranged to withdraw moisture from the isolated discharge passageway. In other instances, desiccant material may be arranged to withdraw moisture from the discharge passageway of the inhaler without isolating the discharge passage during inactivity.

The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.

To provide a pharmaceutical aerosol formulation for use in a pressurized metered dose inhaler (abbreviated as pMDI or MDI), particularly an improved pharmaceutical aerosol formulation for aerosol administration.SOLUTION: The present invention provides a pharmaceutical aerosol suspension formulation for MDI administration, comprising: (a) an atomization β2-stimulant, (b) micronized corticosteroid, (c) a quasi-therapeutic amount of a moisture scavenging excipient, and (d) an HFA propellant. The (a), (b) and (c) and their respective relevant amounts are selected such that they associate to form fluorocarbon having substantially the same density as that of the HFA (hydrofluoroalkane) propellant.SELECTED DRAWING: None

A pharmaceutical aerosol formulation containing pre-micronized epinephrine, a co-solvent ethanol, a surfactant polysorbate 80, and a propellant trans-1, 3, 3, 3-tetrafluoropropene (HFO-1234ze (E)) for use in a pressurized metered dose inhaler is described. The formulations provide efficient delivery of pre-micronized epinephrine particles into the respiratory tract of a patient, and have the advantages of high therapeutic efficacy, improved safety, and low global warming potential (GWP) affecting the environment.

The invention provides a quantitative aerosol inhalation system, which comprises a mouthpiece, a tee joint, a filter, an atomization device, an electromagnetic valve and a one-way valve, and is characterized in that the system is arranged in the tee joint, when a user exhales from the mouthpiece, the one-way valve is opened, airflow flows out of the filter through the one-way valve, when the user inhales, the one-way valve is closed, and the user can only inhale gas flowing in from the atomization device; and the control module is used for receiving the gas pressure value detected by the pressure detection element and controlling the action of the electromagnetic valve according to the gas pressure value. By means of the quantitative aerosol inhalation system, it can be ensured that aerosol administration is conducted on each patient under the optimal inhalation flow, once the inhalation flow is lower than the optimal flow range, administration is stopped immediately, and the accuracy of aerosol administration is greatly improved; meanwhile, the unique one-way valve design is adopted, and cross infection is eradicated; the dosing dosage can be automatically calculated, so that different dosing dosages can be generated by using a single concentration, and the gallipot does not need to be frequently replaced.

A metered dose inhaler valve (26) has a reservoir portion (37) for assembly with a canister (14) for receiving a pressurised formulation of medicament and propellant, a metering valve body (96) defining a metering chamber, and a metering valve stem (24) having an outlet (56) and being axially moveable within the body. The stem moves between a first position in which the chamber is in fluid communication with the canister, and a second position in which the chamber is in fluid communication with the valve stem outlet. A metering valve seal is defined by the valve body and includes an opening through which the stem passes to form a dynamic seal between the stem and at least one of the outside atmosphere and the pressurized canister, where the opening is adapted to be stretched wider by the stem passing through it than it would be absent the valve stem.

The application provides a quantitative injection device, and relates to the technical field of medical injection devices. The quantitative injection device comprises a shell, a dose sleeve, an indicating piece, a rotating assembly, a push rod assembly and a threaded sleeve. The dose sleeve is sleeved on the shell, the rear end of the dose sleeve is provided with a first ratchet, and the dose sleeve is in threaded transmission with the shell. The indicating piece is installed on the shell, and is used for indicating the dose of a medicament. The rotating assembly is installed on the dose sleeve, the rotating assembly is provided with a second ratchet which is engaged with the first ratchet, and the front end of the rotating assembly is provided with a third ratchet. The push rod assembly is installed on the rotating assembly, the push rod assembly is provided with a fourth ratchet which is engaged with the third ratchet, and the rotating assembly can drive the push rod assembly to rotate. The push rod assembly can move in the front-rear direction relative to the threaded sleeve. The embodiment of the application can solve the problem that the injection dose cannot be steplessly adjusted.

A respiratory delivery care system is characterized by comprising: a mechanical flow indicator movable in response to a user's inhalation and / or exhalation, and an electronic indicator operable in response to an electronic signal transmitted in response to the movement of the flow indicator. The flow indicator is an inspiratory valve, an expiratory valve, or an axially movable actuator. The delivery device includes a retaining chamber wound with a coil and at least one magnet disposed at the center of the coil, the at least one magnet being reciprocating to sense current and store the current in a supercapacitor connected to the circuitry and the electronic indicator. A respiratory delivery device is characterized by comprising: a flow indicator configured to transmit a first input signal, a metered-dose inhaler in communication with the retaining chamber, a lever for actuating the inhaler and having a sensor to transmit a second input signal, and a processor for receiving these signals to generate an output signal.

The present disclosure provides a method of treating asthma in a subject at risk of asthma exacerbation, and a method of as-needed treatment or prevention of bronchoconstriction in a subject, and / or prevention of exacerbation in a subject with asthma, comprising administering as needed to the subject a composition comprising therapeutically effective amounts of albuterol and budesonide, wherein the composition is administered via a metered dose inhaler, wherein the method reduces risk of severe asthma exacerbation by at least about 15% as compared to administration of a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation. Also provided is a pharmaceutical composition comprising: albuterol and budesonide in the form of particles; a suspension medium comprising a hydrofluoroolefins (HFO) propellant and / or a hydrofluorocarbon propellant (HFC), and a plurality of respirable suspending particles, wherein the particles of albuterol and budesonide associate with the plurality of respirable suspending particles.

The present invention provides a stable pharmaceutical composition to be used with pressurized metered dose inhalers comprising a beta 2 agonist, a corticosteroid, a muscarinic antagonist, HFO propellant, a co-solvent, an organic acid(s) and optionally water. The invention further provides a specific container and a valve system comprising internally coated canister and a valve for storing the composition. The invention also provides a pharmaceutical composition comprising a beta 2 agonist, a corticosteroid, a muscarinic antagonist for the treatment or prophylaxis of asthma, chronic obstructive pulmonary disease (COPD), rhinitis or as adjunct therapy for cystic fibrosis, non-cystic fibrosis bronchiectasis, lung infections or pulmonary fibrosis.

The present invention relates to pharmaceuticals for inhalation, containing aurothioglucose, and to an inhaler, preferably a powder inhaler, dosing inhaler or atomizer containing such pharmaceuticals. The invention provides these pharmaceuticals for use in the prevention and therapy of pulmonary diseases, in particular infectious and inflammatory-infectious pulmonary diseases. 20 26 20 53 78 07 J ul 2 02 6 2 0 2 6 2 0 2 6 2 0 5 3 7 8 0 7 J u l

The present invention relates to a pressurized metered dose inhaler (pMDI) comprising: a container; a pharmaceutical formation under pressure in the container, said pharmaceutical formulation comprising: (i) about from about 75% by weight to about 87% by weight HFO-1234ze(E); (ii) from about 13% by weight to about 25% by weight of ethanol; and (iii) ipratropium bromide in solution in said ethanol and / or said HFO-1234ze(E); a normally closed valve on the container; and an actuator fluidly connected to the valve and having an orifice diameter of less than 0.5 mm, said valve being actuatable to an open position to release said pharmaceutical formulation to pass through said orifice and produce an aerosol spray containing ipratropium bromide in solution.

The present subject matter discloses an enhancer (100) for delivery of aerosol from a pressurized Metered Dose Inhaler (pMDI, 10) to a user. The enhancer comprises a holding chamber (110), a connector (120) and a one way valve (130). The holding chamber (110) is having a first end (112) configured to receive aerosol from the pMDI (10) and a second end (114) configured to form a mouthpiece (114) for engagement with the user's mouth. The connector (120) is having an adapter end (122) configured to be connected with the pMDI (10) and a pivot end (124) configured to pivotally mount the first end (112) of the holding chamber (110). Further, the connector (120) is configured to swivel the holding chamber (110) around the pivot end (124).

A metered dose inhaler includes ring body open at both ends, the ring body adapted to house a pressurized canister of medicine, an actuator ring including two or more external spring housings containing springs seated and aligned with spring seats formed on a cap attached to the distal end of the ring body the actuator ring fitting over the ring body in concentric fashion partially housing the ring body, the actuator ring having an actuator form fixed to an inside surface thereof to actuate a canister stem installed on the pressurized canister by urging the actuator ring against spring tension over the ring body toward the cap displacing a canister stem to break seal and dispense a dose of medicine.

The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.

Volume spacer with a valve mechanism for inhaled medication delivery, featuring a screw-on mouthpiece and adjustable fitting. It is used in the treatment of respiratory conditions such as asthma, which requires inhaled therapy to prevent attacks and / or hospitalization. The model has a base with a universal inlet compatible with all metered-dose inhalers. The spacer body has two external ridges to improve grip for the patient. Its 177 cubic centimeter volume reduces medication adhesion to the spacer walls, minimizing impact on the oropharynx and ensuring the intended dose reaches the patient's bronchial smooth muscle. This spacer also includes a valve mechanism with a circular base, a concave / convex button, and five trapezoidal holes to prevent medication leakage.It holds and assembles a 1cm wide circular membrane that defines the button at the base. The adaptable nozzle has a screw-on closure, preventing accidental openings, and can be used directly or attached to the mask depending on the patient's age and needs.

Pharmaceutical aerosol formulations containing pre-micronized epinephrine, co-solvent ethanol, surfactant polysorbate 80, and propellant trans-1,3,3,3-tetrafluoropropene (HFO-1234ze(E)) for use in a pressurized metered dose inhaler is described. The formulations provide a highly efficient delivery of pre-micronized epinephrine particles into the patients' respiratory tracts and have the advantages of high efficacy, improved safety, and a low global warming potential (GWP) for environmental impact.

A metered dose inhaler storage container comprises a packaging carton which has openings at opposite ends of the packaging carton comprising an inlet opening at one end of the packaging carton for reception of a mouthpiece of a metered dose inhaler and an associated outlet opening at an opposite end of the packaging carton for engagement by a mouth of a user to inhale medication discharged from the metered dose inhaler through the packaging carton which forms a spacer for the metered dose inhaler. The metered dose inhaler is supplied in the packaging carton and stored within the packaging carton when not in use.The packaging carton forms both a storage container and a spacer for the metered dose inhaler.

The present application relates to pharmaceuticals for inhalation, containing aurothioglucose, and to an inhaler, preferably a powder inhaler, dosing inhaler or atomizer containing such pharmaceuticals. The application provides these pharmaceuticals for use in the prevention and therapy of pulmonary diseases, in particular infectious and inflammatory-infectious pulmonary diseases.

The present disclosure provides a metered dose inhaler (MDI) comprising an API formulation suitable for administration to a patient in need thereof by inhalation, as well as methods and uses of the MDI.